Zika Virus Infections - Pipeline Review, H1 2018

Date: June 15, 2018
Pages: 200
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: Z36B576AADBEN
Leaflet:

Download PDF Leaflet

Zika Virus Infections - Pipeline Review, H1 2018
Zika Virus Infections - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H1 2018, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 1, 34, 25 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 11 and 9 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Zika Virus Infections - Overview
Zika Virus Infections - Therapeutics Development
Zika Virus Infections - Therapeutics Assessment
Zika Virus Infections - Companies Involved in Therapeutics Development
Zika Virus Infections - Drug Profiles
Zika Virus Infections - Dormant Projects
Zika Virus Infections - Discontinued Products
Zika Virus Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Zika Virus Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, H1 2018
Zika Virus Infections - Pipeline by Bharat Biotech Ltd, H1 2018
Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
Zika Virus Infections - Pipeline by Biotron Ltd, H1 2018
Zika Virus Infections - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Zika Virus Infections - Pipeline by Cocrystal Pharma Inc, H1 2018
Zika Virus Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
Zika Virus Infections - Pipeline by Emergex Vaccines Ltd, H1 2018
Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, H1 2018
Zika Virus Infections - Pipeline by Etubics Corp, H1 2018
Zika Virus Infections - Pipeline by GeneOne Life Science Inc, H1 2018
Zika Virus Infections - Pipeline by GeoVax Labs Inc, H1 2018
Zika Virus Infections - Pipeline by Gilead Sciences Inc, H1 2018
Zika Virus Infections - Pipeline by GT Biopharma Inc, H1 2018
Zika Virus Infections - Pipeline by Hawaii Biotech Inc, H1 2018
Zika Virus Infections - Pipeline by Heat Biologics Inc, H1 2018
Zika Virus Infections - Pipeline by Hemispherx Biopharma Inc, H1 2018
Zika Virus Infections - Pipeline by IMV Inc, H1 2018
Zika Virus Infections - Pipeline by Johnson & Johnson, H1 2018
Zika Virus Infections - Pipeline by Kineta Inc, H1 2018
Zika Virus Infections - Pipeline by Moderna Therapeutics Inc, H1 2018
Zika Virus Infections - Pipeline by Mymetics Corp, H1 2018
Zika Virus Infections - Pipeline by NewLink Genetics Corp, H1 2018
Zika Virus Infections - Pipeline by Novalex Therapeutics Inc, H1 2018
Zika Virus Infections - Pipeline by Novavax Inc, H1 2018
Zika Virus Infections - Pipeline by PaxVax Inc, H1 2018
Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H1 2018
Zika Virus Infections - Pipeline by Profectus BioSciences Inc, H1 2018
Zika Virus Infections - Pipeline by Prokarium Ltd, H1 2018
Zika Virus Infections - Pipeline by Replikins Ltd, H1 2018
Zika Virus Infections - Pipeline by Sanofi, H1 2018
Zika Virus Infections - Pipeline by Sirnaomics Inc, H1 2018
Zika Virus Infections - Pipeline by Spotlight Innovation Inc, H1 2018
Zika Virus Infections - Pipeline by Stabilitech Biopharma Ltd, H1 2018
Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, H1 2018
Zika Virus Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Zika Virus Infections - Pipeline by Tamir Biotechnology Inc, H1 2018
Zika Virus Infections - Pipeline by TechnoVax Inc, H1 2018
Zika Virus Infections - Pipeline by Themis Bioscience GmbH, H1 2018
Zika Virus Infections - Pipeline by Theravectys SA, H1 2018
Zika Virus Infections - Pipeline by Valneva SE, H1 2018
Zika Virus Infections - Pipeline by VBI Vaccines Inc, H1 2018
Zika Virus Infections - Pipeline by VLP Therapeutics LLC, H1 2018
Zika Virus Infections - Dormant Projects, H1 2018
Zika Virus Infections - Discontinued Products, H1 2018

LIST OF FIGURES

Number of Products under Development for Zika Virus Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Acuitas Therapeutics Inc
Bharat Biotech Ltd
BioCryst Pharmaceuticals Inc
Biotron Ltd
Chugai Pharmaceutical Co Ltd
Cocrystal Pharma Inc
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
Etubics Corp
GeneOne Life Science Inc
GeoVax Labs Inc
Gilead Sciences Inc
GT Biopharma Inc
Hawaii Biotech Inc
Heat Biologics Inc
Hemispherx Biopharma Inc
IMV Inc
Johnson & Johnson
Kineta Inc
Moderna Therapeutics Inc
Mymetics Corp
NewLink Genetics Corp
Novalex Therapeutics Inc
Novavax Inc
PaxVax Inc
Plex Pharmaceuticals Inc
Profectus BioSciences Inc
Prokarium Ltd
Replikins Ltd
Sanofi
Sirnaomics Inc
Spotlight Innovation Inc
Stabilitech Biopharma Ltd
Starpharma Holdings Ltd
Takeda Pharmaceutical Co Ltd
Tamir Biotechnology Inc
TechnoVax Inc
Themis Bioscience GmbH
Theravectys SA
Valneva SE
VBI Vaccines Inc
VLP Therapeutics LLC
Skip to top


Ask Your Question

Zika Virus Infections - Pipeline Review, H1 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: